- Details
- Neeraj Agarwal, MD discusses the recent update to the CARMENA trial which was presented at ASCO 2019. The Phase 3 non-inferiority CARMENA trial comparing sunitinib versus nephrectomy followed by sunitinib established that patients could avoid nephrectomy without compromising survival. This benefit was seen in both the intermediate and poor risk subgroups. In the updated data presented at ASCO 2019...
|
- Details
- Jens Bedke enthusiastically discusses the transformation in first-line treatment of RCC from monotherapy, which has been the standard of care on the treatment of RCC to now combination therapies. The first-line therapy with a combination of an immune checkpoint inhibitor and a tyrosine kinase inhibitor (TKI) improved outcomes in patients with clear-cell metastatic renal cell carcinoma (mRCC), as c...
|
- Details
- Colleagues, Jaime Landman and Zhamshid Okhunov discuss office-based, ultrasound-guided renal mass biopsy. Jaime details the simplicity of this technique, the best candidate for this procedure, and the value in doing a renal biopsy with this technique. Biographies: Jaime Landman, MD Professor and Chairman, UCI Department of Urology, UC Irvine Medical Center Zhamshid Okhunov, MD, Urology Fellow, Dep...
|
- Details
- Dena Battle, President KCCure joins Jaime Landman and Monty Pal for a discussion on development and establishing resources to assist in the fight against kidney cancer. KCCure, is a research organization that funds high-impact, high-risk kidney cancer research through a peer-review processthrough an expert team of kidney cancer specialists, patients, caregivers, and kidney cancer advocates. The gr...
|
- Details
- (Length of Discussion: 9 min) Alicia Morgans and Toni Choueiri provide a review of the historical background evolving from the era of targeted therapy to the current landscape in kidney cancer incorporating the surprising results from the CARMENA trial. Biographies: Toni K. Choueiri, MD, Jerome and Nancy Kohlberg Professor of Medicine, Harvard Medical School, Attending Physician, Solid Tumor Oncol...
|
- Details
- (Length of discussion - 11 minutes) Kidney cancer, like all cancers, has a spectrum of risk. There are groups of patients with incidentally detected asymptomatic, small renal masses that act relatively indolent and are often over-diagnosed and over-treated in some patients. The issue is defining who they are when they should or should not be treated. Related Content: Watch: Adjuvant Therapies for...
|
- Details
- (Length of discussion - 21 minutes) David Crawford discusses adjuvant therapy in kidney cancer with Robert Uzzo, and the fact that although there have been three decades of trials, there is still no approved therapies to treat the disease. However, Dr. Uzzo points to the S-TRAC trial as a step forward in that research space. Related Content: Watch: Over-treatment of Renal Tumors: The Turtle in the...
|
